Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer. Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells, and cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells. Vaccine-induced immunity to COVID-19 relies mostly on an immunomodulatory T cell response. Therapies such as granulocyte colony-stimulating factor, interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use.

Read more in the app

Why Doesn’t Immunotherapy Work for All Breast Cancers?

Scientists identify gene target to boost effectiveness of cancer immunotherapy

Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer

Why don't T cells destroy solid tumors during immunotherapy?

Preoperative immunotherapy for mesothelioma shows favorable outcomes

CRISPR gene-editing may boost cancer immunotherapy, new study finds

Immunotherapy eliminates disease-causing cells in mice with MS-like disease

New Yale Research Reveals Why Immunotherapy Doesn’t Work for Everybody

New study brings personalized immunotherapy prescriptions a step closer

The protein behind immunotherapy resistance

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Nanotechnology platform enables immune conversion of cancer cells, sensitizing them to immunotherapy

Nanotechnology Breakthrough Makes Cancer Immunotherapy More Effective Against Solid Tumors

Hormone therapy could lower risk of immunotherapy-associated myocarditis in women

Why immunotherapy works well for some cancer patients, but not others

Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma

Cancer-seeking molecular delivery system could boost immunotherapy drug

Cancer biomarker data is not diverse, with implications for immunotherapy patients from underrepresented groups

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

Tumors form temporary structures to avoid immunotherapy treatments